WHO-Backed Study Finds No Remdesivir Benefit for Hospitalized Covid-19 Patients

Result adds to debate over medicine’s utility in treating new coronavirus

The U.S. Food and Drug Administration authorized the emergency use of remdesivir in Covid-19 patients in May.

Photo: Sima Diab/Bloomberg News

A multicountry study funded by the World Health Organization found that the antiviral drug remdesivir, developed by Gilead Sciences Inc., didn’t reduce deaths from Covid-19 in hospitalized patients, a result that adds to debate over the medicine’s utility in treating the new coronavirus.

The WHO study showed that death rates were about the same in hospitalized patients after 28 days whether they received treatment with remdesivir or standard medical care. The study compared remdesivir and other drugs each against standard...

To Read the Full Story

Continue reading your article with
a WSJ membership